新京报讯(记者耿子叶)1月30日，国家(中关村)火炬科创学院主办IQ Talk"智能医工融合创新"活动。 智能医疗器械是全球战略高地，本次活动聚焦新应用新趋势，深度融合创新链、产业链、资金链和人才 链。北京大学第三医院普通外科教授原春辉指出，AI将在诊断、决策和健康管理发挥重要作用，实现 从"治好病"到精准高效微创治疗。清华大学的卡洛.维托里奥.坎尼斯特拉奇教授呼吁政府支持生物医药 领域研发可解释、稀疏化人工智能。他表示，密集型人工智能模型往往不具备可解释性，应用于医学诊 断存在风险。稀疏神经网络拥有无可比拟的可解释性，这是其与生物医药领域融合的先决条件。 "四链"人才代表北京航空航天大学冯林教授指出，微纳米机器人等颠覆性技术研发周期长、投入大、不 确定性强，需要耐心稳定投入和吸引社会资本参与以加速产业化。术锐机器人邢玉柱表示，手术机器人 降低患者创伤，提升安全性和可及性；市场化需适配医院运营模式、付费机制和诊疗流程。康桥资本赵 迎红表示，医疗赛道有技术、监管、市场挑战，估值应从并购视角反推，投资需评估技术先进性、临床 价值和商业化能力。北京机器人融资租赁高展表示，通过租赁模式推动手术机器人入院，降低门槛，建 ...

Core Insights - The integration of AI in the medical field is expanding, impacting areas such as drug development, medical imaging, disease diagnosis, and health monitoring [1][2] - AI diagnostic tools are evolving from single-use assistants to comprehensive partners in the treatment process, particularly in orthopedic surgery [1] - Investment in high-quality data and targeted funding is crucial for shaping the global pharmaceutical and healthcare landscape [1] Group 1: AI Applications in Healthcare - AI technology is increasingly applied in various medical domains, including new drug development, imaging, and intelligent rehabilitation [1] - The development of intelligent surgical robots for fracture treatment addresses critical challenges in minimally invasive procedures, significantly improving treatment outcomes [1] Group 2: Investment and Innovation - Investment strategies should focus on technology transfer and clinical needs to drive innovation in smart medical devices [1] - The development of disruptive technologies like micro-nano robots requires stable capital investment and participation from social capital to accelerate industrialization [2] Group 3: Collaborative Ecosystem - A multi-win ecosystem involving medical, industrial, financial, research, and application sectors is essential for promoting the adoption of surgical robots in hospitals [2] - The event aims to facilitate talent exchange and promote the development of the intelligent medical device industry in Beijing [2]

Core Viewpoint - The article invites innovative individuals in the medical health and life sciences sector to showcase their groundbreaking ideas or products, emphasizing the importance of early-stage projects that can impress investors [2]. Group 1: Event Overview - The event aims to create a platform for early-stage medical technology innovators to present their ideas to over 200 top-tier investors [2]. - Participants will have the opportunity to be featured on the "2025 Notable Hard Technology Innovators" list, enhancing their visibility and credibility in the industry [2]. - The event will take place in Hangzhou on September 24-25, linking over 100 early-stage AI and hard technology companies with active investment institutions [6]. Group 2: Participation Criteria - Companies must be registered in China, operate independently, and have a demonstrable product or service, even if it is still in the PPT stage [3][4]. - The ideal participants are young, innovative, and possess strong technical skills, with a preference for those who have not previously engaged with venture capital [4]. - Focus areas include biotechnology, synthetic biology, medical solution platforms, and smart medical devices [5]. Group 3: Judging Panel - The judging panel consists of notable figures from various investment firms, including: - Li Fangli from Zijin Port Capital [10] - Liu Miao from SoftBank China [12] - Lu Gang from Chuangdong Investment [14] - Song Gao from Northern Light Venture Capital [18] - Sun Jingwei from Tengye Venture Capital [20] - Tian Tian from Yuyin Medical Fund [24]